Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
- PMID: 2084073
- DOI: 10.1007/BF00198598
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
Abstract
Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical